×

U.S. high court speeds copycat biologic drugs to market

WASHINGTON, June 12 (Reuters) - The U.S. Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of dollars in sales for drug companies.

The justices, in a 9-0 ruling, overturned a lower court decision that had prevented Swiss pharmaceutical company Novartis AG from selling its copycat version of California-based Amgen Inc's Neupogen until six months after the U.S. Food and Drug Administration approved it.

(Reporting by Andrew Chung; Editing by Will Dunham)